In the elevated plus-maze test of anxiety the scores of control animals remain stable over repeated tests. However, a single prior exposure to the plus-maze renders an animal insensitive to the anxiolytic effects of chlordiazepoxide. This phenomenon of “one-trial tolerance” persisted even when the two trials were separated by as much as 2 weeks. It has previously been shown that the drug state of the animal on trial 1 is not important to the development of the phenomenon, but one-trial tolerance did not develop if a very high dose (75 mg/kg) of chlordiazepoxide was given on trial 1; it is suggested that this is due to the amnesic effects of the drug. The learning on trial 1 was not specific to a particular plus-maze and tolerance could be observed even when the maze on trial 1 was made from different material. The crucial experience on trial 1 was experience of an open arm of the maze. Whereas tolerance could be obtained as a result of a previous plus-maze experience, there was no evidence of an anxiogenic withdrawal response when rats were tested the following day undrugged. The phenomenon of one-trial tolerance is explained within our recently proposed two-factor theory of benzodiazepine dependence; it is suggested that one-trial tolerance provides a method for studying the mechanism underlying the development of tolerance to anxiolytic effects, independently from the mechanism underlying the development of withdrawal responses.
This is a preview of subscription content, log in to check access.
Buy single article
Instant access to the full article PDF.
Price includes VAT for USA
Subscribe to journal
Immediate online access to all issues from 2019. Subscription will auto renew annually.
This is the net price. Taxes to be calculated in checkout.
Cooper SJ, Burnett G, Brown K (1981) Food preference following acute or chronic chlordiazepoxide administration: tolerance to an antineophobic action. Psychopharmacology 73:70–74
File SE (1985) Tolerance to the behavioral actions of benzodiazepines. Neurosci Biobehav Rev 9:113–121
File SE (1990) One-trial tolerance to the anxiolytic effects of chlordiazepoxide in the plus-maze. Psychopharmacology 100:281–282
File SE, Baldwin HA (1989) Changes in anxiety in rats tolerant to, and withdrawn from, benzodiazepines: behavioural and biochemical studies. In: Tyrer P (ed) Psychopharmacology of anxiety. Oxford University Press, Oxford, pp 28–51
File SE, Hitchcott PK (1990) A theory of benzodiazepine dependence that can explain whether flumazenil will enhance or reverse the phenomena. Psychopharmacology (in press)
File SE, Baldwin HA, Aranko K (1987) Anxiogenic effects from benzodiazepine withdrawal are linked to the development of tolerance. Brain Res Bull 19:607–610
Gallager DW, Lakoski JM, Gonsalves SF, Rauch SL (1984) Chronic benzodiazepine treatment decreases postsynaptic GABA sensitivity. Nature 308:74–77
Gonzales JP, McCulloch AJ, Nicholls PJ, Sewell RDE, Tekle A (1984) Subacute benzodiazepine treatment: observations on behavioural tolerance and withdrawal. Alcohol Alcohol 19:325–332
Lister RG (1985) The amnesic effects of benzodiazepines in man. Neurosci Biobehav Rev 9:87–94
Lister RG (1987) The use of a plus-maze to measure anxiety in the mouse. Psychopharmacology 92:180–185
Pellow S, Chopin P, File SE, Briley M (1985) Validation of open: closed arm entries in an elevated plus-maze as a measure of anxiety in the rat. J Neurosci Methods 14:149–167
Soderpalm B (1987) Pharmacology of the benzodiazepines, with special emphasis on alprazolam. Acta Psychiatr Scand 76:39–46
Treit D (1985) Evidence that tolerance develops to the anxiolytic effect of diazepam in rats. Pharmacol Biochem Behav 22:383–387
Vellucci SV, File SE (1979) Chlordiazepoxide loses its anxiolytic action with long-term treatment. Psychopharmacology 62:61–65
About this article
Cite this article
File, S.E., Mabbutt, P.S. & Hitchcott, P.K. Characterisation of the phenomenon of “one-trial tolerance” to the anxiolytic effect of chlordiazepoxide in the elevated plus-maze. Psychopharmacology 102, 98–101 (1990). https://doi.org/10.1007/BF02245751
- Benzodiazepine dependence